|
Edasalonexent Slows DMD Progression in Phase 2 Trial
|
|
Phase 2 study results of edasalonexent, an investigational oral small molecule NF-kB inhibitor for the treatment of Duchenne muscular dystrophy (DMD), suggest that the therapy is associated with slowed disease progression, as well as a good safety profile over the course of more than 50 patient-years of exposure in boys with the disease. |
|
Read more
|
|
|
| Tecfidera Generic Granted Tentative FDA Approval as Patent Assault Continues |
|
The US Food and Drug Administration (FDA) has granted tentative approval to Glenmark Pharmaceuticals for dimethyl fumarate delayed-release capsules, a generic version of Biogen's Tecfidera. |
|
Read more
|
|
|
